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1. Introduction
According to the American Cancer Society, in 2012 ovarian cancer is expected to account for
3% (22,280) of all new cases and 6% (15,500) of all female cancer deaths in the United States.
The proportion of ovarian cancer among gynaecological cancers is increasing, also because of
the decrease in cervical cancer as a result of pap smear screening programmes. On the other
hand, survival from ovarian cancer is the poorest of all gynaecological cancers, with a five-
year relative survival rate of 44% for all stages [1,2]. The main reasons for this poor survival
are the lack of early detection strategies and an unfavourable anatomical situation. Thus, the
vast majority of ovarian cancer is diagnosed at an advanced stage and therapy for this
pathology is very complex [3-5]. Reduction in mortality rates could be gained both with new
screening strategies and with ameliorations in surgical and medical treatments. However,
neither of these approaches will affect cancer incidence, thus, it is clear that the prospects for
making a major impact on the mortality from ovarian cancer lie more in the area of prevention.
The purpose of this chapter is to identify the evidence for the appropriate practical strategies
to prevent ovarian cancer or the detection of cancer in the early stages in order to improve the
overall survival. The search was restricted to full reports and guidelines published in English
between 2000 and May 2012, in an attempt to summarize the principal findings regarding
primary and secondary ovarian cancer prevention.
2. Primary prevention for ovarian cancer in general population
Primary prevention aims to prevent the disease before its biological onset, thus it is based on
avoiding risk factors and increasing protective factors.
© 2013 Cortesi et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
A summary of the most significant risk and protective factors, with relative hazard ratio, for
epithelial ovarian cancer is summarized in Tables 1a and1b,
AUTHORS RISK FACTORS RR (95% CI)
Schorge JO et al. [6] White race 1.35 (1.08-1.50)
Schouten LJ et al. [7] Height≥160 cm 1.38 (1.16-1.65)
Lahmann PH et al. [8] BMI≥25 1.33 (1.05-1.68)
Camargo MC et al. [9] Asbestos exposure 1.77 (1.37-2.28)
Cramer DW [10] early age at menarche 1.74 (1.28-2.18)
Cramer DW [10] late menopause 1.61 (1.15-2.08)
Beral V et al. [11] HRT 1.20 (0.98-1.32)
Melin A et al. [12] Endometriosis 1.43 (1.19-1.71)
Chen S et al. [13] BRCA1BRCA2
42.4 (15-119.6)
20.6 (7.75-57.2)
Watson P et al. [14] MMR 19 (5.0-30.0)
(a)
AUTHORS PROTECTIVE FACTORS HR (95% CI)
Trudel D et al. [15] green tea components 0.66 (0.54-0.80)
Collaborative Group on
Epidemiological Studies of Ovarian
Cancer [16]
hormonal contraceptive use 0.73 (0.70-0.76)
Ness RB et al. [17] Multiparity(≥ 4 pregnancies) 0.40 (0.30-0.50)
Danforth KN et al. [18] breastfeeding 0.98 per month( 0.97-1.00)
Hankinson SE et al. [19] bilateral tube ligation 0.33 (0.16-0.64)
Hankinson SE et al. [19] hysterectomy 0.67 (0.45-1.00)
(b)
Table 1. (a) Main significant risk factors for ovarian cancer. (b) Main significant protective factors for ovarian cancer.
The average age at diagnosis is approximately 60 years, but the overall incidence of ovarian
cancer rises with increasing age up to 75-84 years, due to the accumulation of random genetic
alterations, before declining slightly among women beyond 84 years [20]. Women residing in
North America, Northern Europe or in any industrialized Western country have a higher risk
of developing ovarian cancer. Conversely, women residing in developing countries have
shown the lowest rate [6]. The exact reasons for this distribution are unknown but discrepan‐
cies in parity, rates of gynaecologic surgery and dietary habits may account for some differ‐
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ences [21]. In particular, regarding dietary habits, a comprehensive meta-analysis of the
observational studies published up to September 2011 provided no evidence of a material
association between alcohol drinking and epithelial ovarian cancer risk [22]. Finally, a recent
study provided some suggestion that soy and phytoestrogen consumption may decrease
ovarian cancer risk, although the results did not reach statistical significance [23].
Exposure to radiation may increase the risk of ovarian cancer and the risk increases with
increasing dose. The Life Span Study incidence data for ovarian cancer demonstrated a
borderline significant association [24], and mortality data showed a significant positive
association between exposure to radiation and ovarian cancer [25].
With regards to reproductive factors, early age at menarche and late menopause have been
consistently associated with an increased risk of ovarian cancer, likely due to an increase in
ovulation and in oestrogen exposure [26]. The effect of combined hormonal contraceptive use
on the risk of ovarian cancer has been long discussed. In 2007, the IARC review concluded that
women who had at least for a period used combined hormonal contraceptives orally had an
overall reduced risk for ovarian cancer, which persists for at least 20 years after cessation of
use, and an inverse relationship was observed with duration of use [27]. These results have
been confirmed by the Collaborative Group on Epidemiological Studies of Ovarian Cancer [16]
that reported an overall reduction in ovarian cancer risk in users versus non-users of 27%,
which was not confined to any particular type of oral formulation nor to any histological type
of ovarian cancer, although it was less consistent for mucinous than for other types of ovarian
cancer. On this basis, the “incessant menstruation” hypothesis was postulated, which con‐
cludes that the use of oral contraceptives (OC) should be favoured for prolonged periods of
time, especially in women with endometriosis, a population at doubled risk of ovarian cancer
[28]. On the other hand, in the Million Women Study HRT after menopause was shown to
increase the risk of ovarian cancer [11].
Women who have never had children are at increased risk of developing ovarian cancer [29].
Regarding fertility drug use, previous studies have provided conflicting results. Recent data
demonstrated that fertility drug use does not significantly contribute to ovarian cancer risk
among the majority of women. However, women who despite their use remain nulliparous
may have an increased risk [30]. The role of breastfeeding as a protective factor against ovarian
cancer has been long discussed. Finally, the risk of ovarian cancer decreases in women who
underwent bilateral tube ligation or hysterectomy, probably because these surgical interven‐
tions do not allow the carcinogenic agents to enter the body from the vagina and reach the
ovaries [19, 31]. For instance, a number of observational studies (largely case-control) con‐
ducted over the last two decades suggested an association between use of talc powders on the
female perineum and increased risk of ovarian cancer, although the weak statistical associa‐
tions observed in a number of epidemiological studies do not support a causal association
between cosmetic talc use and ovarian cancer [32,33].
Endometriosis represents another considerable risk factor for epithelial ovarian cancer. In
particular, self-reported endometriosis was associated with a significantly increased risk of
clear-cell, low-grade serous and endometrioid invasive ovarian cancers. No association was
noted between endometriosis and risk of mucinous or high-grade serous invasive ovarian
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cancers or borderline tumours of either subtype [34]. Also, pelvic inflammatory disease has
been suggested to double the risk of epithelial ovarian cancer [35], but few studies have been
done and the conclusions are inconsistent.
The most important risk factor still remains a family history of breast or ovarian cancer. Up to
10% of ovarian cancer patients may have inherited a germline mutation that places them at in‐
creased risk of the disease. Mutations in the breast and ovarian cancer-susceptibility genes
BRCA1 and BRCA2 confer an increased lifetime risk of ovarian cancer. BRCA1 and BRCA2 are
tumour suppressor genes involved in many cellular functions to prevent carcinogenesis [Fig.1].
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Figure 1. BrCa1 protein functions.
The mechanism to repair the double-strand DNA breaks is shown in Fig.2.
–
Figure 2. Repair of double-strand DNA breaks by BRCA1 and BRCA2 genes.
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Heterozygous germline mutation leads to genetic instability as shown in the Fig.3, modified
by Brodie et al. [36]
 
 
–Figure 3. Genetic instability in the germline and somatic BrCa1 mutations [36].
However, BRCA mutations do not account for the entire range of hereditary ovarian can‐
cer  syndromes.  Other  hereditary  epithelial  ovarian cancers  are  attributed to  Lynch syn‐
drome.  Lynch  syndrome  is  an  autosomal  dominant  disorder,  which  predisposes  to
colorectal cancer, endometrial cancer, ovarian, gastric, small bowel, biliary/pancreatic, uro‐
thelial, skin, and central nervous system cancers. The cumulative risk of ovarian cancer is
estimated to  be  8–10%,  with  an  average  age  at  onset  of  42  years  [14].  Moreover,  other
genes  often associated with  rare  cancer  syndromes such as  TP53  and PTEN,  or  CHEK2
and PALB2  confer  a  low to  moderate  risk  of  breast  and ovarian  cancer  [37-39].  Recent
technological  advances  have  aided  in  the  recognition  of  additional  tumour  suppressor
genes  potentially  associated  with  hereditary  breast  cancer,  such  as  RAD51  and  BARD1
[40]. To date, at least 16 genes have been associated with hereditary ovarian cancer, most‐
ly involved in the FA-BRCA  pathway and the mismatch repair  system. However,  many
families with suspicious pedigrees do not have a specific mutation identified through clin‐
ical testing, due to a currently undetectable BRCA1/2  mutation or a mutation in another
susceptibility  gene.  Although  their  cancer  risks  are  not  as  well  defined,  these  families
should be considered as part of the hereditary breast and/or ovarian cancer spectrum [13].
However, most of the common risk and protective factors only slightly influence the risk of
developing ovarian cancer, thus, to date; the knowledge of these factors has still not been
translated into practical strategies to prevent ovarian cancer.
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3. Primary prevention for ovarian cancer in high risk women
Some women have a high risk of developing ovarian cancer due to hereditary conditions
associated to BRCA syndrome and Lynch syndrome. Thus, when one of these forms of
hereditary or familial breast and/or ovarian cancer is suspected in clinical practice, the general
practitioner should refer the patient to a cancer centre specialising in cancer-specific genetic
counselling for the identification, definition and management of risk. Genetic counselling,
defined by the American Society of Human Genetics as ‘a communication process which deals
with the human problems associated with the occurrence or risk of occurrence of a genetic
disorder in a family’, involves one or more professional figures to help the affected individuals
or families [41-44]. Genetic counselling in the oncological setting (cancer-specific genetic
counselling) should also provide sufficient information to enable the user to make a fully
informed choice as to course of action, particularly with regards to prevention, in the case of
the identification of a mutation or of a familial cancer risk [45, 46].
A recent review investigated the impact of cancer genetic risk assessment on outcomes,
including perceived risk of inherited cancer and psychological distress. The review found
favourable outcomes for patients after risk assessment for familial breast cancer, suggesting
that cancer-specific genetic risk assessment services help to reduce distress, improve the
accuracy of the perception of risk of ovarian cancer, and increase the knowledge of ovarian
cancer and genetics. However, there were too few papers to make any significant conclusions
on how best to deliver cancer genetic risk assessment services. Further research is needed,
assessing the best means of delivering cancer risk evaluation, by different health professionals,
in different ways and in alternative locations [47].
Women at increased risk of breast and ovarian cancer are advised to consider risk-reducing
strategies; however, such methods vary in their effectiveness. These strategies include
chemoprevention and prophylactic surgery (risk-reducing salpingo-oophorectomy, RRSO).
Risk-reducing strategies have been shown to have associations with a lengthening of life
expectancy in BRCA1/2 carriers.
3.1. Risk-reducing salpingo-oophorectomy (RRSO)
Women who have inherited mutations in the BRCA1 or BRCA2 genes have substantially
elevated risks of breast and ovarian cancer, with a lifetime risk of breast cancer of 56%–84%
[48-51]. Breast cancer in BRCA1/2 mutation carriers also occurs at an earlier age, particularly
among the BRCA1 mutation carriers, than in non-carriers. The risk for ovarian cancer depends
on whether the mutation has occurred in BRCA1 or BRCA2, with estimated risks ranging from
34% to 44% for BRCA1 mutation carriers and from 12% to 25% for BRCA2 mutation carriers
[48, 49, 52-54]. Carriers of BRCA1/2 mutations are counselled to help them interpret the
implications of these elevated risks, choose strategies to reduce these risks, and maximize early
detection of cancers. The risk of breast cancer can be reduced either with RRSO and/or
mastectomy or non-surgically (i.e. with chemoprevention). However, due to the lack of
effective screening for ovarian cancer, RRSO is usually strongly recommended to BRCA1/2
mutation carriers once childbearing is complete.
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RRSO has also been demonstrated to decrease the risk of both breast and ovarian cancer in
BRCA1/2 mutation carriers [55-60]. However, the studies examining the extent of risk reduction
have used different designs; some are retrospective case–control studies, while others used a
prospective cohort design. In a large, retrospective analysis of 551 BRCA carriers, RRSO was
found to reduce the risk of ovarian cancer by 96% and breast cancer by 53% at a mean follow-
up of 9 years [55]. A multicentre prospective study, Kauff et al. [56] found that, during a 3-year
follow-up, RRSO was associated with an 85% reduction in BRCA1-associated gynaecologic
cancer risk and a 72% reduction in BRCA2-associated breast cancer risk. Although protection
against BRCA1-associated breast cancer and BRCA2-associated gynaecologic cancer was
suggested, neither effect reached statistical significance. The authors postulate that the
protection conferred by RRSO against breast and gynaecologic cancers may differ between the
carriers of BRCA1 and BRCA2 mutations.
Similar findings were observed in a prospective study of 170 BRCA carriers. During a mean fol‐
low-up of 2 years, the incidence of ovarian or peritoneal cancer and breast cancer was significant‐
ly greater amongst those women who selected surveillance than amongst those who chose to
undergo RRSO [59.] Even among prospective studies, the inclusion criteria and the definitions of
follow-up time differ. In some studies, only unaffected mutation-positive women are included
and followed up. In others, particularly when examining ovarian cancer risk, women with breast
cancer are included. Such differences in study design can introduce biases (such as the survival
bias) and can have an impact on risk reduction estimates. For example, the reported efficacy of
RRSO in reducing the risk of ovarian/fallopian tube cancers varies from 71% to 96% [55-61]. Al‐
though these estimates imply a substantial reduction in risk, this variability may affect the deci‐
sions of premenopausal women who are making a decision about whether to undergo a
treatment that will cause abrupt and premature menopause. Patients and their physicians need
as much information as possible regarding the efficacy of RRSO in reducing cancer risk to bal‐
ance this benefit with the health risks caused by premature entry into menopause.
A summary of published studies on RRSO is presented in Table 2.
Reference Studydesign
With/Without
RRSO MYFU
OC
Risk Reduction
(%)
BC
Risk Reduction
(%)
Rebbeck et al., 2002 [55] RC 261/292 8.5 96 53
Kauff et al., 2008 [56] PC 509/283 3.2 85 72
Finch et al., 2006 [57] RC 1041/779 3.5 80 NA
Chang-Claude et al., 2007 [58] RC 55/1601 65,675 PY NA 44
Rutter et al., 2003 [60] RC 5/223 NA 67 NA
Kauff et al., 2002 [61] PC 98/72 2.0 85 68
PC = prospective cohort; RC = retrospective cohort; MYFU = mean years of follow-up; PY = person-years; NR = not reported;
and NA = not applicable; RRSO = risk-reducing salpingo-oophorectomy.
Table 2. Published studies on risk-reducing salpingo-oophorectomy in BrCa1and/ or BrCa2 mutation carriers.
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A synopsis of different management strategies available for BRCA1 and BRCA2 mutation
carriers is shown in Table 3.
Management options
Gynecologic cancer Strategy Advantage Limitation
Chemoprevention OC Likely 30-60% reductionin ovarian cancer risk
Potential increase in risk
of breast cancer
Screening TVUS, CA 125 Avoids RRSO Unproven efficacy
Risk-reducing surgery Bilateral salpingo-oophorectomy
Substantial decrease in
risk of ovarian and
fallopian tube cancers
Premature menopause
and iatrogenic infertility
TVUS= Transvaginal Ultrasound; RRSO = risk-reducing salpingo-oophorectomy
Table 3. Synopsis of different prevention strategies for BRCA1 and BRCA2 mutation carriers.
The National Comprehensive Cancer Network (NCCN) guidelines and other institutions
concerning this method, recommend RRSO “for women with a known BRCA1/2 mutation,
ideally between 35 and 40 years or upon completion of child bearing” or at an adjusted age
based on earliest age of ovarian cancer diagnosis in the family” [62].
Also ACOG, the Committee on Genetics and the Society of Gyneacologic Oncologists,
recommends RRSO for women with BRCA1/2 mutations, by the age of 40 years or when
childbearing is complete [63].
The National Cancer Institute (NCI) [64] on the clinical management of BRCA mutation carriers
considers, besides salpingo-oophorectomy, bilateral salpingectomy as an interim procedure
to reduce risk in BRCA mutation carriers. There are no data available on the efficacy of
salpingectomy as a risk-reducing procedure. The procedure preserves ovarian function and
spares the premenopausal patient the adverse effects of a premature menopause. It can be
performed using a minimally invasive approach, and a subsequent bilateral oophorectomy
could be deferred until the patient approaches menopause. While the data make the compel‐
ling argument that some pelvic serous cancers in BRCA mutation carriers originate in the
fallopian tube, clearly, some cancers arise in the ovary. Furthermore, bilateral salpingectomy
could give patients a false sense of security that they have eliminated their cancer risk as
completely as if they had undergone a bilateral salpingo-oophorectomy. A small study of 14
young BRCA mutation carriers documented the procedure as feasible [65]. However, efficacy
and impact on ovarian function was not assessed in this study. Future prospective trials are
needed to establish the validity of the procedure as a risk-reducing intervention.
For the European Society of Medical Oncology ESMO [66], RRSO is associated with a reduction
in risk of breast cancer in premenopausal BRCA mutation carriers, a reduction in risk of ovarian
cancer, and there is evidence of a reduction in overall mortality [67]. RRSO is recommended
after the age of 35 and when childbearing decisions are complete.
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The significantly reduced risk of breast cancer by RRSO seems to be higher in BRCA2 mutation
carriers than in BRCA1 carriers. Several reports have addressed this question although
additional research is required [56]. Short-term HRT after RRSO seems not to decrease the
overall benefit of this strategy for breast cancer risk reduction [68].
However, it should be noted that the NCCN and other institutions couch these recommenda‐
tions within a multidisciplinary consultative process in which reproductive desires, assess‐
ment of cancer risk, and the pros and cons of surgery along with the potential sequelae of
surgery are fully discussed.
The recommendations of different organizations regarding surgical primary prevention for
BRCA1/2 mutation carriers are shown in Table 4.
Management options NCCN [62]
ACOG Committee
on Genetics and the
Society of
Gynecologic
Oncologists [63]
National Cancer
Institute (NCI)
[64]
ESMO [65]
RRSO
Between 35 and 40
years or upon
completion of child
bearing
By the age of 40 years
or when childbearing
is complete
Considered but
age is not
indicated
After age 35 and
when
childbearing
decisions are
complete
Bilateral salpingectomy - -
Considered but
age is not
indicated
-
Table 4. Recommendations of several organizations regarding primary prevention for BRCA mutation carriers.
3.2. Chemoprevention
Women at increased risk, based on their personal or family history of breast and/or ovarian
cancer including BRCA1/2 mutation carriers, may join a cancer prevention clinical trial or a
chemoprevention trial. OC have been the most widely studied chemopreventive agents in
ovarian cancer. Recently, Iodice et al. conducted a meta-analysis updated to March 2010 on the
association between OC use and breast or ovarian cancer in BRCA1/2 mutation carriers [69].
Based on 18 studies a total of 2855 breast cancer cases and 1503 ovarian cancer cases carrying
an ascertained BRCA1/2 mutation were included. As previously noted, use of OC at any point
during one’s life was associated with a 50% reduction in relative risk of developing ovarian
cancer for BRCA1/2 mutation carriers. Looking specifically at duration of use, each 10-year
period of OC use resulted in a 36% relative risk reduction in the development of ovarian cancer.
However, the meta-analysis showed no evidence of a significant association between OC use
and breast cancer risk. Notably, formulations used before 1975 correlated with an increased
risk of breast cancer, but there was no correlation with the use of more recent formulations. A
summary of the association between OC use and ovarian cancer risk in mutation carriers is
shown in Table 5.
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EXPOSURE GENES WITHMUTATION
CATEGORIES OF
EXPOSURE No. of STUDIES No. of CASES HR (95% CI)
OC USERS
BRCA 1/2
Users
5 1503 0.50 (0.33-0.75)
BRCA 1 5 1251 0.51 (0.40-0.65)
BRCA 2 4 286 0.52 (0.31-0.87)
DURATION OF USE BRCA 1/2
1 year
4 1336
0.96 (0.94-0.97)
5 years 0.80 (0.73-0.88)
10 years 0.64 (0.53-0.78)
Table 5. Summary of the association between OC use and ovarian cancer risk in mutation carriers
Another meta-analysis of cohort, case-control and case-case studies published in English up
to December 2009 confirmed a significantly decreased ovarian cancer risk in BRCA1/2 mutation
carriers associated with the use of OC, while a significantly increased risk in breast cancer was
only shown in a subset of cohort studies on BRCA1 mutation carriers. To conclude, OC use
can be considered as an alternative strategy in the chemoprevention of ovarian cancer in
BRCA1 mutation carriers who do not accept RRSO above the age of 30 years [70].
Other chemopreventative agents such as retinoids, vitamin D, cyclo-oxygenase inhibitors and
peroxisome proliferator activated receptor-gamma ligands have shown promise in early
investigations of disease prevention [71].
Retinoids, a class of compounds comprising vitamin A, its natural derivatives, and synthetic
analogs, have been extensively studied in both the prevention and treatment of gynaecologic
malignancies [72]. One of the most promising retinoids to be used in chemoprevention trials
is the synthetic amide of retinoic acid fenretinide, N-4-hydroxyphenyl retinamide (4-HPR). 4-
HPR has been found to have significant chemopreventive action in a large variety of in vitro
and in vivo systems. Since both fenretinide and its major metabolite, 4-metoxyphenyl retina‐
mide (MPR), selectively accumulate in the human breast, evaluation of 4-HPR as a chemopre‐
ventive agent in breast cancer has been particularly attractive [73]. The most important clinical
trials with 4-HPR are mentioned in Table 6.
The most important study where 4-HPR was administrated was a multicentric phase III
randomized trial, coordinated by the Istituto Nazionale dei Tumori in Milan, which started in
1987. Most notably, the younger the women were, the greater the benefit of 4-HPR. Such a
benefit was associated with a remarkable 50% risk reduction in women aged 40 years or
younger, whereas it disappeared after 55 years of age. Interestingly, the incidence of ovarian
cancer during the 5-year intervention period was significantly lower in the treatment arm [74].
The role of analgesic drug use in the development of ovarian cancer is still widely discussed.
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STUDY DESIGN TREATMENT END POINTS OUTCOMES
Costa et al.,
1989 [75]
Phase I,
Randomized,
Placebo controlled
(60)
Orally: 100, 200 and
300mg x 6 months
subsequently at
200mg for another 6
months.
Tolerability
Recommended dose for
chemoprevention trials of HPR
is 200mg/die.
Formelli et
al., 1989
[76]
Phase II,
Randomized,
Placebo controlled
(60)
Orally: 100, 200 and
300mg x 6 months
subsequently at
200mg for another 6
months.
Pharmacokinetic
HPR treatment lowers retinol
and RPB plasma
concentrations. Effect related
to HPR levels and reversible on
cessation of HPR
administration.
Veronesi et
al., 1999
[77]
Phase III,
Randomized
(2867)
Orally 200mg versus
no treatment x 5
years.
Second breast
cancer prevention
No statistically significant effect
but a possible benefit in
premenopausal women.
Veronesi et
al., 2006
[78]
Phase III,
Randomized, 15-
year follow-up
(1879)
Orally 200mg versus
no treatment x 5
years: 15-years
followup.
Second breast
cancer prevention
4-HPR induces a significant
reduction of risk of second
breast cancer in
premenopausal women, which
is remarkable at younger ages,
and persists several years after
treatment cessation.
HPR: fenretinide, RBP: retinol-binding protein.
Table 6. Clinical trials with 4-HPR [74].
A recent population-based case-control study, carried out in Denmark in the period 1995-1999,
analysed the association between analgesic drug use and ovarian cancer risk using multiple
logistic regression models. The study showed that regular use of non-aspirin non-steroidal
anti-inflammatory drugs (NA-NSAID), paracetamol or other analgesics did not decrease
ovarian cancer risk. In contrast, use of any analgesics (OR = 0.72; 95% CI 0.53-0.98) or aspirin
(OR = 0.60; 95% CI 0.36-1.00) resulted in a statistically significant decreased risk of serous
ovarian cancer but not mucinous or other ovarian tumours [79]. On the other hand, recent data
reported by the Multiethnic Cohort Study did not find compelling evidence to support an
association between use of NSAID and risk of ovarian and endometrial cancers in a multiethnic
population. The RR (95% CI) for ovarian cancer associated with aspirin, non-aspirin NSAID,
and acetaminophen were 0.87 (0.68, 1.14), 0.97 (0.74, 1.26), and 0.86 (0.67, 1.12), respectively.
No heterogeneity across ethnic groups (P's ≥0.29) or dose-response relation with increased
duration of use (P's for trend ≥0.16) was observed [80]. Finally, in an attempt to review and
summarize the evidence provided by longitudinal studies on the association between NSAID
use and ovarian cancer risk, a comprehensive literature search for articles published up to
December 2011 was performed (Table 7). The meta-analysis found no evidence of an associa‐
tion between aspirin or NA-NSAID use and ovarian cancer risk, based on a random-effects
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model or a fixed-effects model. Furthermore, the analysis did not show strong association
between frequency or duration of NA-NSAID use and ovarian cancer, leading to the conclu‐
sion that there is no strong evidence of an association between aspirin/NA-NSAID use and
ovarian cancer [81].
No. Of
studies Fixed-effects model Random-effects model P-value
RR (95% CI) RR (95% CI)
ASPIRIN USE
All studies 17 0,94 (0,87-1,01) 0,91 (0,82-1,01) 0,046
C-C studies 14 0,94 (0,87-1,02) 0,90 (0,79-1,03) 0,015
Cohort studies 3 0,92 (0,77-1,09) 0,92 (0,77-1,10) 0,456
Regular Use 7 0,86 (0,73-1,03) 0,83 (0,65-1,05) 0,119
Irregular Use 7 1,07 (0,96-1,20) 1,07 (0,96-1,21) 0,421
Duration > 5 yrs 5 0,91 (0,67-1,24) 0,89 (0,63-1,25) 0,332
NA-NSAID use
All studies 7 0,86 (0,76-0,98) 0,89 (0,74-1,08) 0,089
C-C studies 4 0,88 (0,75-1,03) 0,97 (0,73-1,28) 0,042
Cohort studies 3 0,82 (0,64-1,04) 0,89 (0,74-1,08) 0,283
Regular Use 3 1,45 (1,07-1,98) 1,47 (0,95-2,27) 0,153
Irregular Use 3 0,96 (0,69-1,33) 0,93 (0,49-1,76) 0,038
Duration > 5 yrs 3 1,65 (1,13-2,41) 1,56 (0,92-2,65) 0,21
NA-NSAID: non aspirin- non-steroidal anti-inflammatory drugs
Table 7. Metanalysis of longitudinal studies on the association between NSAID use and ovarian cancer risk
4. Secondary prevention for ovarian cancer
This is based on diagnosing and treating extant disease in the early stages before it causes signif‐
icant morbidity. CA125 (or MUC16) glycoprotein is the most studied tumour marker, alone
and/or in combination with other biomarkers, for ovarian cancer screening. However, false pos‐
itive CA125 levels can occur in women with benign conditions, including menstruation, appen‐
dicitis, benign ovarian cysts, endometriosis and pelvic inflammatory disease, as well as with
other malignancies, including breast, lung, endometrial and pancreatic cancers. Thus, a large
number of false-positive screening tests can occur, potentially leading to unnecessary surgeries
and subsequent issues of morbidity and cost [82]. Consequently, multimodal strategies, in par‐
ticular the combination of CA125 with pelvic ultrasound, have been examined, in order to im‐
prove sensitivity and positive predictive value of ovarian cancer screening.
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4.1. Transvaginal ultrasound
In the general population, TVUS appears to be superior to transabdominal ultrasound in the pre‐
operative diagnosis of adnexal masses. Both techniques have lower specificity in premenopaus‐
al  women  than  in  postmenopausal  women  due  to  the  cyclic  menstrual  changes  in
premenopausal ovaries (e.g., transient corpus luteum cysts) that can cause difficulty in the inter‐
pretation. The randomized prospective Prostate, Lung, Colorectal, and Ovarian Cancer Screen‐
ing Trial found no reduction in mortality with the annual use of combined TVUS and CA125 in
screening asymptomatic, postmenopausal women at average risk of ovarian cancer [83].
Data are limited regarding the potential benefit of TVUS in screening women at inherited risk
of ovarian cancer. A number of retrospective studies have reported experiments with ovarian
cancer screening in high-risk women using TVUS with or without CA125 [84-90].
However, there is little uniformity in the definition of high-risk criteria and compliance with
screening, and in whether the cancers detected were incident or prevalent. One of the largest re‐
ported studies included 888 BRCA1/BRCA2 mutation carriers who were annually screened
with TVUS and CA125. Ten women developed ovarian cancer; five of the ten developed inter‐
val cancers after normal screening results within 3 to 10 months before diagnosis. Five of the ten
ovarian cancers were screen-detected incident cases, which had had normal screening results
within 6 to 14 months before diagnosis. Out of these five cases, four were stage IIIB or IV [85].
A similar study reported the results of annual TVUS and CA125 combined-screening in a
cohort of 312 high-risk women (152 BRCA1/BRCA2 mutation carriers) [86]. Out of four cancers
detected because of abnormal TVUS and CA125, all cases were symptomatic, and three had
an advanced-stage disease. Annual screening of BRCA1/BRCA2 mutation carriers with pelvic
ultrasound, TVUS, and CA125 failed to detect early-stage ovarian cancer among 241 women
in a study from the Netherlands [87]. Three cancers were detected over the course of the study,
all advanced stage IIIC disease. Finally, a study of 1,100 moderate- and high-risk women who
underwent annual TVUS and CA125 combined screening reported that ten out of 13 ovarian
tumours were detected due to screening. Only five out of ten were stage I or II [88]. There are
limited data related to the efficacy of semiannual screening with TVUS and CA125 [89].
The first prospective study of TVUS and CA125 with survival as the primary outcome was com‐
pleted in 2009. Out of 3,532 high-risk women screened, 981 were BRCA mutation carriers, of
which 49 developed ovarian cancer. The 5- and 10-year survival was 58.6% (95% CI, 50.9–66.3)
and 36% (95% CI, 27–45), respectively, and there was no difference in survival between carriers
and non-carriers. A major limitation of the study was the absence of a control group. Despite
these limitations, this study suggests that annual surveillance by TVUS and CA125 level appears
to be ineffective in detecting tumours at an early stage to substantially influence survival [90].
4.2. Serum CA125
Serum  CA125  screening  for  ovarian  cancer  in  high-risk  women  has  been  evaluated  in
combination with TVUS in a number of retrospective studies, as described in the previous
section [84-90].
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The National Institutes of Health (NIH) Consensus Statement on Ovarian Cancer recommend‐
ed against routine screening of the general population for ovarian cancer with serum CA125.
The NIH Consensus Statement did, however, recommend that women at inherited risk of
ovarian cancer undergo TVUS and serum CA125 screening every 6 to 12 months, beginning
at the age of 35 years [91]. The Cancer Genetics Studies Consortium task force recommends
that female carriers of a deleterious BRCA1 mutation undergo annual or semi-annual screening
using TVUS and serum CA125 levels, beginning at age of 25 to 35 years [92]. Both recommen‐
dations are based solely on expert opinion and best clinical judgment.
NCCN for those patients who have not chosen RRSO, consider concurrent TVUS (preferably
day 1-10 menstrual cycle women in premenopausal women) + CA125 (preferably after day 5
of menstrual cycle women in premenopausal women) every 6 months starting at the age of 30
years or 5-10 years before the earliest age of first diagnosis of ovarian cancer in the family [93].
Although there are retrospective data indicating that annual ovarian cancer screening using
TVUS and measurement of serum CA125 levels is neither an effective strategy for the early
detection of ovarian tumours nor a reasonable substitute for a bilateral RRSO, the effectiveness
of these interventions is limited to six-monthly screening. Investigational imaging and
screening studies may be considered for this population.
4.3. Proton Magnetic Resonance Spectroscopy (MRS)
MRS has proved to be a reliable technique for probing metabolic patterns, biochemical effects
of tumour microenvironment, and the action of therapy in cancer cells, both in vivo and in
vitro [94]. In particular, an increase in the total choline-containing compounds (tCho) content
allows to distinguish malignant from benign lesions in the breast [95].
Moreover, some studies have also shown alterations of the phospholipid metabolism in vitro
using epithelial ovarian carcinoma cell lines [96,97], and demonstrated the feasibility of 3D CSI
MRS to detect a choline peak in ovarian lesions in vivo at 1.5 T.
Then, the metabolic meaning of a high concentration of choline in ovarian tumours merits
some consideration. This topic has been extensively reviewed by Podo et al. in 2007 [98]. The
high choline concentration of ovarian tumours can be considered as the result of an inappro‐
priate storage attributable to metabolic deregulation associated with clinical indicators of
increased malignancy. The possibility of using a spatially resolved approach for MRS of
ovarian masses opens an intriguing prospect for the diagnosis of early-stage tumours, with
potential impact on the overall survival. This is especially true for carriers of a BRCA mutation,
with a lifetime risk of 39% to 46% among women with the BRCA1 mutation and a risk of 12%
to 20% among those with the BRCA2 mutation [99].
Based on peer-reviewed published data, several institutions established the Guidelines to
facilitate clinical management of patients with a suggestive personal or family history of breast
and/or ovarian cancer, in particular individuals from a family with a known deleterious
BRCA1/2 mutation. Screening options include transvaginal ultrasonography (TVUS), and
serum CA125, while prevention options include medical therapy with drugs and surgery such
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as RRSO. The guidelines, summarized in Table 8, include age ranges for which these options
should be begun and how often screening should take place. [53].
Management options NCCN [62]
ACOG Committee on Genetics
and the Society of
Gynecologic Oncologists [63]
National Cancer
Institute (NCI)
[64]
ESMO [65]
Surveillance
TVU+CA125 Every 6 months startingat age 30 years
Periodic screening beginning
between the ages 30 years and
35years
Every 6 to 12
months, beginning
at age 35 years
Not considered
Surgery
RRSO
Between 35 and 40
years or upon
completion of child
bearing
By age 40 years or when
childbearing is complete
Considered but
age is not
indicated
After age 35 and
when childbearing
decisions are
complete
Bilateral salpingectomy - -
Considered but
age is not
indicated
-
Chemoprevention Considered Considered Considered Not considered
Investigational imaging
and screening studies Considered Considered Considered Not considered
Table 8. Published Guidelines/Consensus Statements for the management of BRCA mutation carriers.
4.4. Human Epididymis Protein 4 (HE4)
Additional potential serum biomarkers have been studied for the detection of ovarian cancer.
For instance, human epididymis protein 4 (HE4) is a secreted glycoprotein over-expressed by
serous and endometrioid ovarian cancers and expressed by 32% of ovarian cancers lacking
CA125 expression.
To define the clinical utility of HE4, a comprehensive assessment of HE4 protein expression
in benign and malignant ovarian and non-ovarian tissues by immunohistochemistry was
performed and published in 2005. In comparison with normal surface epithelium, which does
not express the protein, HE4 was widely found in cortical inclusion cysts lined by metaplastic
Mullerian epithelium. These findings suggested that the formation of Mullerian epithelium is
a prerequisite step in the development of some types of epithelial ovarian cancer. Moreover,
the expression was restricted to certain histologic subtypes: 93% of serous and 100% of
endometrioid epithelial ovarian cancers expressed HE4, while only 50% and 0% of clear cell
carcinomas and mucinous tumours, respectively, were positive. HE4 protein expression is
restricted in normal tissue to the reproductive tracts and respiratory epithelium. In fact, tissue
microarrays revealed that the majority of non-ovarian carcinomas do not express HE4 [100].
In 2008 the Food and Drug Administration (FDA) approved HE4 to monitor disease recurrence
and this marker was recently incorporated into the clinical evaluation of ovarian cancer
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patients. Recently, Moore et al. published a series of papers that used a combination of CA125,
HE4 and menopausal status to predict the presence of a malignant ovarian tumour and
developed the Risk of Ovarian Malignancy Algorithm (ROMA), a simple biomarker based
algorithm, which requires US [101, 102].
In the last few years, several multi-modal screenings of women at high risk, combining
different approaches, were carried out to improve ovarian cancer diagnostic test performance
[103,104]. In 2010, a prospective case-control study was designed to evaluate the independent
contributions of HE4, CA125 and the Symptom Index (SI) to predict ovarian cancer status in
a multivariate model [105]. The SI is a screening tool that evaluates specific symptoms in
conjunction with their frequency and duration to identify women who are at risk of ovarian
cancer [106]. The SI, HE4 and CA125 all made significant independent contributions to ovarian
cancer prediction. A rule for the positive cut-off based on anyone of the three tests being
positive had a sensitivity of 95% with specificity of 80%. A rule based on any two of the three
tests being positive had a sensitivity of 84% with a specificity of 98.5%. The SI alone had
sensitivity of 64% with specificity of 88%. If the SI index is used to select women for CA125
and HE4 testing, specificity is 98.5% and sensitivity is 58% using the 2-of-3-positive positive
cut-off rule. A comparison between different markers in ovarian cancer early diagnosis is
presented in Table 9.
SCREENING TESTS DESCRIPTION
Single Markers
CA125 CA125 was dichotomized at 95th percentile in the control group. Subjects with amarker value above that threshold were considered to be positive for CA125.
HE4 HE4 was dichotomized at 95th percentile in the control group. Subjects with a markervalue above that threshold were considered to be positive for HE4.
Symptom Index (SI)
The SI was considered to be positive if the patient had at least one of the following
symptoms for less than one year but more than 12 times per month: bloating or
increased abdominal size, abdominal or pelvic pain, difficulty eating or feeling full
quickly.
Marker Combinations
CA125 or HE4 Screen considered positive if CA125, HE4 or both were positive.
SI or CA125 Screen considered positive if either the SI or CA125 was positive, or if both werepositive.
SI or HE4 Screen considered positive if either the SI or HE4 was positive, or if both were positive.
Any 1 of 3 tests positive Screen considered positive if any one of the SI or CA125 or HE4 was positive, or if twoor more tests were positive.
Any 2 of 3 tests positive
Screen considered positive if both the SI and CA125 were positive, or if both the SI
and HE4 were positive, or if both CA125 and HE4 were positive, or if all three tests
were positive.
SI and at least 1 additional test
positive
Classified as positive if SI was positive in addition to either a positive CA125 or a
positive HE4, or if all three tests were positive.
Table 9. Description of screening tests and biomarker combinations.
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4.5. Proteomic profiling of ovarian cancer for biomarker discovery
Unfortunately, current diagnostic tools have had very limited success in early detection. The
search for an ovarian cancer screening method with improved specificity and sensitivity has
led to the examination of serum biomarker patterns using new ‘omic’ technologies [107-110].
In recent years, the advancing techniques for proteomics have accelerated the research for
ovarian cancer biomarkers. Numerous proteomics-based molecular biomarkers/panels have
been identified and hold great potential for diagnostic applications, but they need further
development and validation.
Several studies have analysed the proteomic profiles of ovarian tumour tissue, cell lines, urine,
ascites fluid and blood samples from ovarian cancer patients (Table 10) [111- 114].
AUTHORS IDENTIFIED BIOMARKER REGULATION IN CANCER
An et al.,(2006)[111]
NM23-H1 ↑
Annexin-1 ↑
Protein phosphatase-1 ↑
Ferritin light chain ↑
Proteasome alpha-6 ↑
NAGK (N-acetyl glucosamine kinase) ↑
Petri et al., (2009) [112]
fibrinogen alpha fragment ↑
collagen alpha 1 (III) fragment ↑
fibrinogen beta NT fragment ↑
Li et al., (2009) [113]
prx-II ↓
prx-III ↑
hsp27 ↑
hsp60 ↑
mitochondrial short-chain enoyl-CoA hydratase ↑
Prohibitin ↑
Cortesi et al.,(2011) [114]
Annexin-5 (ANXA5) ↓
Phosphatidylethanolamine-biding protein 1 (PEBP) ↓
glutathione S-transferase A2 (GSTA2) ↓
galectin-3 (LEG3) ↓
protein S100-A8-calgranulin A (S100A8) ↑
retinol binding protein (RET1) ↓
Table 10. Promising biomarkers discovered by proteomic technology for ovarian cancer diagnosis.
An et al. [111] identified that different histologic subtypes of ovarian malignant epithelial
tumours showed distinctly different protein expression profiles. The potential candidate
biomarkers screened in ovarian tumours and found to be significantly up-regulated in
comparison to normal tissues were: NM23, annexin-1, protein phosphatase-1, ferritin light
chain, proteasome R-6, and NAGK (N-acetylglucosamine kinase). More recently, Petri et al.
[112] examined whether urine could be used to measure specific ovarian cancer proteomic
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profiles and whether one peak alone or in combination with CA125 or other peaks had the
sensitivity and specificity to discriminate between ovarian cancer pelvic mass and benign
pelvic mass. Twenty-one significantly different peaks (p<0.001) were examined and the three
most significant peaks were identified as fibrinogen alpha fragment, collagen alpha 1 (III)
fragment and fibrinogen beta NT fragment. These results supported the feasibility of using
urine as a diagnostic tool and suggested the enhanced prediction performance of combined
marker analysis. Li et al. [113] performed a comparative proteomic study of normal ovarian
epithelial and ovarian epithelial serous cystadenocarcinoma tissue and identified six proteins
significantly differentially expressed. In particular, Prx-II expression was found to be linearly
decreased from normal ovarian tissue, to benign ovarian lesions, and ovarian malignancies.
No statistical difference between carcinoma groups in different clinical stages, differentiation
status, and histological type was seen, suggesting that the decreased level of Prx-II is a common
marker for ovarian malignancies. This was the first report on the altered expression of Prx-II
in ovarian cancer.
A recent comparative proteomic study investigated and defined protein expression patterns
associated with advanced stage ovarian cancer, to define a panel of diagnostic and/or prog‐
nostic markers. The study also investigated proteins secreted by the cancer cell into the
interstitial fluid, as cancer growth and progression also depends on stromal factors present in
the tumour microenvironment. Moreover, many biomarkers present in biopsied cancer tissues
can also be found in blood serum, representing potential biomarkers of the disease. Proteomic
profiling of differentially expressed proteins in cancer ovarian tissue, tumoral interstitial fluid
(TIF) and ascitic fluid, compared with healthy tissue samples and normal interstitial fluid
(NIF), allowed the identification of protein spots consistently differentially expressed between
normal and cancer samples. Protein expression/identification was evaluated by 2-DE (two-
dimensional gel electrophoresis) and MS (mass spectrometry) analysis and was confirmed by
immunohistochemistry. Six proteins showed differential expression in tumoral interstitial
fluid and tumour tissue compared to normal interstitial fluid and healthy tissue. Differential
protein expression between tumoral and normal ovarian tissue is presented in Table 11.
PROTEIN NAME FOLD CHANGE TUMORALVERSUS NORMAL TISSUE P-value
FOLD CHANGE TIF
VERSUS NIF P-value
ANXA5 -1,88 ± -0,48 <0,0001 -5,605 ± -3,29 <0,01
PEBP -4,21 ± -2,90 <0,01 -2,82 ± -0,69 <0,0001
GSTA2 -4,67 ± -1,88 <0,0001 -27,39 ± -21,24 <0,01
LEG3 -2,19 ± -0,69 <0,0001 -5,10 ± -4,42 <0,05
S100A8 3,67 ± 1,50 <0,001 3,58 ± 1,11 <0,0001
RET1 -6,33 ± -3,30 <0,001 -5,01 ± -4,28 <0,05
The fold change indicates the direction and the magnitude of the change in expression level. Data are expressed as mean
± standard deviation.
Table 11. Modification in protein expression in tumoral tissue and interstitial fluid
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Five were found to be down-regulated and identified as galectin 3, glutathione S-transferase
A-2, retinol binding protein 1, phosphatidylethanolamine-binding protein and annexin 5,
while the calgranulin, was significantly up-regulated in all pathological samples, including
the ascitic fluid. This is the first study to report an over-expression of calgranulin by 2-DE
analysis combined with MS/MS on surgical biopsy. As previously reported, the reduced
expression of galectin 3 and retinol binding protein 1 in cystic fluid and serum of patients with
early stage disease is confirmed in this study. The results highlight alterations in proteins that
control cell-cycle progression and apoptosis, as well as factors that modulate the activity of
signal transduction pathways. Moreover, this study suggests that calgranulin expression may
be used as a diagnostic and/or prognostic biomarker [114].
However, critical assessment of the results has shown significant shortcomings and uncer‐
tainties with regard to the reproducibility of the findings and identity of the proteins behind
the peak patterns, thus, the validation of the newly discovered biomarkers still remains the
most challenging aspect of clinical proteomics. The advancing techniques for proteomics have
shown promise in a variety of studies and have provided new insights into ovarian cancer
diagnosis, but few have turned out to be useful in the clinic. At present, the development of
an effective strategy for early detection of ovarian cancer is still a work in progress [110].
5. Discussion
Primary and secondary prevention of ovarian cancer play a crucial role in the attempt to
improve the overall survival from the disease. In particular, primary prevention is based on
avoiding risk factors and increasing protective factors. Despite the identification of several risk
and protective factors among the general population, most of the common factors described
to date only slightly influence the risk of developing ovarian cancer, thus, the knowledge of
these factors has still not been translated into practical strategies to prevent ovarian cancer.
On the other hand, primary prevention could represent a good opportunity for high-risk
women. Women who inherit a mutation in either the BRCA1 or BRCA2 gene have greatly
elevated lifetime risks of ovarian cancer, fallopian tube cancer and breast cancer. Surveillance
for ovarian and fallopian tube cancer has not been proven to be effective. For this reason,
preventive surgical removal of the ovaries and fallopian tubes (salpingo-oophorectomy) is
actively recommended to these women by the age of 35 or 40 years, often prior to natural
menopause, to prevent cancer. Moreover, women at increased risk may join a cancer preven‐
tion clinical trial or a chemoprevention trial. In particular, oral contraceptive use can be
considered as an alternative strategy in the chemoprevention of ovarian cancer in BRCA1
mutation carriers who do not accept RRSO above the age of 30 years. Other chemopreventive
agents such as retinoids, analgesic drugs, vitamin D, cyclo-oxygenase inhibitors and peroxi‐
some proliferator activated receptor-gamma ligands have shown promise in early investiga‐
tions of disease prevention.
Regarding radiological methods to investigate ovaries and their adnexes, new techniques
besides TVUS need to be explored. Pelvic Magnetic Radiological Imaging could be of interest
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even if it is difficult to imagine such an expensive technique being employed in the screening
of high-risk women. For high-risk women, recommended cancer screening strategies, which
need to be adjusted depending on the earliest age of onset in a family, have not been assessed
by randomized trials or case-control studies. Ovarian cancer screening relies on a combination
of annual or semi-annual pelvic examination, annual or semi-annual transvaginal ultrasound
examination with colour Doppler, and annual measurement of serum CA125 concentrations.
Current approaches are a futile attempt to detect ovarian cancer in the early stages, but future
research should be directed to better characterizing critical pathways in ovarian carcinogenesis
and to identifying appropriate surveillance programs based on biomarker tests and/or
radiological investigations, in order to improve overall survival, which dramatically decreases
in the first 5 years. Due to the fact that an analysis of potentially thousands of proteins which
could be simultaneously altered is necessary, comparative proteomics is a promising mode of
potential biomarker discovery for cancer detection and monitoring. A better estimation of the
biological importance of certain proteins with regard to the progression from pre-neoplastic
tissue alterations to malignant tumours, as well as the prediction of the metastasis-forming
potential by biomarkers, will be a necessary prerequisite to provide a more detailed insight
and understanding of tumour progression.
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